A strong gene interaction between HLA-DQ1 and DQ2 alleles has been associated with anti-Ro/SSA autoantibodies ( HLA-DQ1/DQ2 heterozygotes is most closely related to antiRo/SSA autoantibodies, thereby supporting a gene complementation mechanism. Beyond this effect, an RFLP associated with HLA-DQ2 and/or DR7 is also related to Ro/SSA precipitins. Multiple molecular histocompatibility mechanisms are implicated, therefore, in the production of anti-Ro/SSA autoantibodies in autoimmune disease. For anti-Ro/SSA autoantibodies in SLE, and perhaps more generally, these data show that the histocompatibility antigens are among the elements that confer autoimmune response specificity and restrict the production of particular autoantibodies among patients with systemic lupus erythematosus. (J. Clin. Invest. 1990. 86:606-611.)
Introduction
For many immunogens the immune responsiveness found in Fl mice but in neither parental inbred mouse strain is the consequence of gene complementation of the class II histocompatibility molecules (1, 2) . Though abundant evidence exists that analogous dimeric af3 molecules are present in man (3) (4) (5) , examples ofgene complementation demonstrating an in vivo human immune response are lacking. High titers of anti-Ro/SSA autoantibody predominate in HLA-DQl/DQ2 heterozygous patients with primary Sjogren's syndrome (6) and systemic lupus erythematosus (SLE) (7, 8) . This gene interaction effect may also be an instance of possible gene complementation ofthe immune response genes which is examined at the gene level in this study.
Ro/SSA is an RNA-protein complex of unknown cellular function composed of a peptide complexed with one of four small uridine-rich RNAs which are transcribed by RNA polymerase III (9) . In addition to the well known 60-kD Ro/SSA peptide (10-12), 52-and 54-kD peptides have been recently defined (13, 14) . Available data also support binding ofthe 52 kD Ro/SSA peptide to the hY RNAs (13). Present evidence supports anti-Ro/SSA having an immunopathogenic role in congenital complete heart block as well as in some of the SLE and Sjogren's syndrome patients who have nephritis, sialadenitis, photosensitive dermatitis, or vasculitis (15) (16) (17) (18) (19) (20) (21) (22) .
To better understand the gene interaction at HLA-DQ associated with anti-Ro/SSA antibodies, we have analyzed the relationship between restriction fragment length polymorphisms (RFLP)' of the DQa and DQ# genes to HLA antigens and anti-Ro/SSA autoantibodies in SLE patients. Ro/SSA precipitins were found in nearly all SLE patients who had a particular pair of RFLPs. One is detected by a DQa probe and associated with HLA-DQl positive SLE patients and the other RFLP is detected by a DQB probe in HLA-DQ2-positive patients. Moreover, this effect was stronger than any single allele whether defined by HLA serology or by RFLP analysis at HLA-DQ. Beyond this effect, however, a single RFLP was found to also be associated with Ro/SSA precipitins. These data not only show that gene complementation of HLA may be important in human immune responses, but also suggest that multiple molecular components of the normal immune apparatus determine the specificity of autoimmune responses.
Methods
Patients and anti-RoISSA antibody. Informed consent and peripheral blood was obtained from 76 patients who satisfied the 1982 revised American Rheumatism Association classification criteria for systemic lupus erythematosus (SLE) (23 The RFLP of each group most closely associated with the presence of a Ro/SSA precipitin was selected as a representative for subsequent analysis. Since the DQ1a and DQ2,B RFLPs together were the most closely related to the HLA-DQ1/DQ2 heterozygotes (Table I) , this pair was predicted to be more closely associated with the presence of Ro/SSA precipitins than any other combination of HLA-DQl and DQ2 RFLPs. The RFLP data from 67 SLE patients were used to test this hypothesis by stepwise logistic regression (32) . The four possible pairwise combinations related to HLA-DQI and DQ2 ofthe four RFLP groups (DQl a and DQ2a, DQl a and DQ2f, DQ I 3 and DQ2a, and DQ IB and DQ2,B) were evaluated for their possible contribution to anti-Ro/SSA (Table II) . Only the DQ1a and DQ23 RFLP combination represented by the Pvu 11 4.8 kb (DQa) and Pvu 11 1.7 kb (DQp) was incorporated into Other effects between RFLPs and anti-Ro/SSA may also be present and they may be as important as or more important than the DQIa and DQ2#t RFLP combination in other cohorts of SLE patients. To detect such additional effects in this sample of SLE patients, model building with stepwise logistic regression has been continued by including all RFLPs associated with Ro/SSA precipitins as potential independent variables along with the DQla and DQ2I# RFLP combination.
Associations ofindividual RFLPs with anti-Ro/SSA have been found only with the DQft gene probe. They include an Eco RV 20.0 kb fragment (P = 0.002) as well as two RFLPs of the DQ2f3 RFLP group, Pvu 11 1.7 kb and Bam HI 4.2 kb (P < 0.005). These RFLPs, along with three other RFLPs less closely associated with Ro/SSA precipitins, have been evaluated individually and together along with the DQ I a and DQ2# RFLP combination in stepwise logistic regression models of anti-Ro/SSA. The DQla and DQ2I# RFLP combination has always made the greatest contribution to each model and is consistently incorporated first (Table IV) . Subsequently, only the Eco RV 20.0 kb RFLP detected with the DQK3 probe is incorporated into the model. The Eco RV 20.0 kb RFLP is associated with HLA-DR7 in these SLE patients (P < 0.003) nearly all of whom are HLA-DQ2 positive as has been found in normal donors by others (35) (36) (37) . This RFLP did not hybridize to a DR# gene probe (38) and therefore does not reflect variation at HLA-DR. Unlike the HLA-DQ 1/DQ2 effect (Table II) The distribution of HLA alleles in human populations as well as the linkage disequilibrium found between alleles at different HLA loci are known to vary between ethnic groups. For example, the HLA-B8 and HLA-DR3 are found together in North American whites more frequently than expected and with other associated alleles constitute a haplotype not ordinarily found in other ethnic groups (35) . As noted above a third of the SLE patients in this cohort are black and twothirds are white (Table III) . The frequencies of the HLA-DQ1 and DQ2 serologic alleles as well as the DQl or DQ2 associated RFLPs (Table I) the Eco RV 20-kb RFLP and the DQla and DQ2(# RFLP combination require an allele associated with HLA-DQ2. This is consistent with the DQ# RFLPs of HLA-DQ2 being strongly associated with anti-Ro/SSA. Third, the presence oftwo histocompatibility antigens related to an autoantibody in SLE is consistent with the proposed model for clinical heterogeneity of SLE where once the individual expresses the now unknown fundamental immune defect of SLE, the particular autoantibodies produced are determined at least in part by histocompatibility composition (7) . Fourth, since the anti-Ro/SSA precipitin results were identical in this group of SLE patients with bovine and human Ro/SSA antigen sources, the recently appreciated species variation in the Ro/SSA antigen does not influence these results (46) . The complexity of the Ro/SSA immune response as reflected by the multiple Ro/SSA peptides suggests that additional levels of immune discrimination will be found with the analysis of more restricted antigenic specificities of the Ro/SSA antigenic particle.
There is good evidence for the DQla and DQ2,B RFLPs reflecting allelic variants at HLA-DQ. First, each is strongly associated in this SLE patient group with an HLA-DQ serologically defined allele. Second, there is no evidence of cross-hybridization to HLA-DR with any DQ2(# group RFLP since a DR# probe (38) failed to hybridize to any of DQ2# RFLPs.
Third, both RFLPs from the DQla and DQ2,B groups are most closely associated with DQ alleles in other studies (36, 37, 47) .
Further, the data support another allele at the DR# or the DQJ# locus which is associated with the HLA-DQ2, DR7 haplotype being related to Ro/SSA precipitins. These results support the existence of multiple class II molecular mechanisms for the anti-Ro/SSA autoimmune response in SLE. One is likely to involve an ad heterodimer gene complementation product of the HLA-DQ locus, while in a second a class II # peptide gene product at HLA-DR7 or HLA-DQ2 is important. Moreover, these histocompatibility alleles must serve as restriction elements for the autoimmune response in SLE. Hence, some of the variation in autoimmune response between SLE patients may be attributed to differences in histocompatibility composition, thereby demonstrating an important analogy to the immune response against ordinary, nonautoimmune antigens. The conclusion follows that the autoimmune response in the example of anti-Ro/SSA in SLE is dependent upon an antigen and is not the result of autonomous B lymphocyte activation. These data define some of the normal molecular machinery of the immune response used in generating an autoimmune antibody response.
